AU1971200A - Assays for compounds which increase phospholipase a2 activity - Google Patents

Assays for compounds which increase phospholipase a2 activity

Info

Publication number
AU1971200A
AU1971200A AU19712/00A AU1971200A AU1971200A AU 1971200 A AU1971200 A AU 1971200A AU 19712/00 A AU19712/00 A AU 19712/00A AU 1971200 A AU1971200 A AU 1971200A AU 1971200 A AU1971200 A AU 1971200A
Authority
AU
Australia
Prior art keywords
assays
activity
compounds
phospholipase
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19712/00A
Inventor
David John Heal
Keith Frank Martin
Kevin Stuart John Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of AU1971200A publication Critical patent/AU1971200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
AU19712/00A 1998-12-08 1999-12-07 Assays for compounds which increase phospholipase a2 activity Abandoned AU1971200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826899.8A GB9826899D0 (en) 1998-12-08 1998-12-08 Methods to treat depression and other psychiatric disorders and assays for compounds
GB9826899 1998-12-08
PCT/EP1999/009546 WO2000034791A1 (en) 1998-12-08 1999-12-07 Assays for compounds which increase phospholipase a2 activity

Publications (1)

Publication Number Publication Date
AU1971200A true AU1971200A (en) 2000-06-26

Family

ID=10843783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19712/00A Abandoned AU1971200A (en) 1998-12-08 1999-12-07 Assays for compounds which increase phospholipase a2 activity

Country Status (6)

Country Link
EP (1) EP1137949A1 (en)
JP (1) JP2002532687A (en)
AU (1) AU1971200A (en)
CA (1) CA2353616A1 (en)
GB (1) GB9826899D0 (en)
WO (1) WO2000034791A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001703D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Assay
KR20030046896A (en) * 2001-12-07 2003-06-18 학교법인 포항공과대학교 Transformant having a recombinant reporter gene whose expression being regulated by glucocorticoid and method for screening analogue and inhibitor of glucocorticoid using same
ATE503998T1 (en) * 2002-02-21 2011-04-15 Tokyo Gas Co Ltd TEST AGENTS FOR ASSESSING THE PHARMACOLOGICAL ACTION OF A DRUG AND METHOD AND REAGENTS FOR SCREENING A DRUG WITH EXCELLENT ADMINISTRATION EFFECTS AND/OR LOW SIDE EFFECTS COMPRISING ENZYMES, ENZYMIN HIBITORS OR RECEPTOR LIGANDS DRUGS AND/O THE PRODRUGS OF IT
EP2466312B1 (en) * 2009-08-12 2019-10-16 Human Metabolome Technologies, Inc. Phosphoethanolamine as biomarker of depression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2

Also Published As

Publication number Publication date
GB9826899D0 (en) 1999-01-27
JP2002532687A (en) 2002-10-02
WO2000034791A1 (en) 2000-06-15
EP1137949A1 (en) 2001-10-04
CA2353616A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
EP0928996A3 (en) Toner preparation processes
EP0928991A3 (en) Toner preparation processes
EP0928992A3 (en) Toner preparation processes
AU8547198A (en) Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxido squalene-cyclase
AU6804098A (en) Triazinylaminostilbene compounds
AU5052199A (en) Chemical compounds
AU1424200A (en) Compounds
EP0928994A3 (en) Toner preparation processes
AU4501699A (en) Aminoazole compounds
AU5637499A (en) Chemical compounds iii
AU2014800A (en) Novel compounds
AU5980899A (en) Novel compounds
AU6104599A (en) Chemical compounds viii
AU1434500A (en) Compounds
AU4814699A (en) Novel compounds
AU7124598A (en) Polymer-platinum compounds
AUPP042397A0 (en) 5-arylpyrazole compounds
AU4835599A (en) Assay for homocysteine
AU1950899A (en) Compounds for increased bioavailability
AU1971200A (en) Assays for compounds which increase phospholipase a2 activity
AU3843899A (en) Apoptosis-inducing compounds
AU1090800A (en) Linker-assisted immunoassay for glyphosate
AU2187799A (en) Novel taxaneterpine compounds
AU8019998A (en) Fluoromethoximino compounds
AU1872900A (en) Chemical compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase